Targeted genetic and viral therapy for advanced head and neck cancers

Drug Discovery Today

Volumn 14, Issue 11-12, 2009, Pages 570-578

  Huang, Pin I ^a,b   Chang, Ju Fang ^c   Kirn, David H ^d,e   Liu, Ta Chiang ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Jennerex Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; FLUOROURACIL; G 207; GENDICINE; H 101; KH 901; METHOTREXATE; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; ONYX 015; PACLITAXEL; PROTEIN P53; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GENE EXPRESSION; GENE MUTATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INJECTION SITE PAIN; LARYNX CANCER; LEUKOPENIA; LIVER METASTASIS; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; NAUSEA; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; ONCOLYTIC VIROTHERAPY;

EID: 67349252613     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.03.008     Document Type: Review

References (105)

1. Argiris A., et al. Head and neck cancer. Lancet 371 (2008) 1695-1709
2. Forastiere A.A. Chemotherapy in the treatment of locally advanced head and neck cancer. J. Surg. Oncol. 97 (2008) 701-707
3. Brockstein B., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann. Oncol. 15 (2004) 1179-1186
4. Bonner J.A., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
5. Pfister D.G., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24 (2006) 1072-1078
6. Burtness B. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin. Biol. Ther. 5 (2005) 1085-1093
7. Chung C.H., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 358 (2008) 1109-1117
8. O'Neil B.H., et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J. Clin. Oncol. 25 (2007) 3644-3648
9. Edelstein M.L., et al. Gene therapy clinical trials worldwide to 2007-an update. J. Gene Med. 9 (2007) 833-842
10. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 13 (2006) 921-926
11. Brennan J.A., et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332 (1995) 429-435
12. Poeta M.L., et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 357 (2007) 2552-2561
13. Harrington K.J., et al. Gene therapy for head and neck cancer. Cancer Metast. Rev. 24 (2005) 147-164
14. Clayman G.L., et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol. 16 (1998) 2221-2232
15. Clayman G.L., et al. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin. Cancer Res. 5 (1999) 1715-1722
16. Han D.M., et al. Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: Phase I clinical trial and follow up. Zhonghua Yi Xue Za Zhi 83 (2003) 2029-2032
17. Zhang S.W., et al. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a Phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi 83 (2003) 2023-2028
18. Chen C.B., et al. Recombinant adenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: a Phase II clinical trial. Zhonghua Yi Xue Za Zhi 83 (2003) 2033-2035
19. Pan J.J., et al. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27 (2009) 799-804
20. Zhang S.W., et al. Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma. Zhonghua Zhong Liu Za Zhi 27 (2005) 426-428
21. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 (2005) 1016-1027
22. Gabrilovich D.I. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin. Biol. Ther. 6 (2006) 823-832
23. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy-introgen, RPR/INGN 201. Drugs R&D 8 (2007) 176-187
24. Tolcher A.W., et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J. Clin. Oncol. 24 (2006) 2052-2058
25. Breitbach C.J., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15 (2007) 1686-1693
26. Liu T.C., et al. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4 (2007) 101-117
27. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther. 8 (2001) 89-98
28. Freeman A.I., et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 13 (2006) 221-228
29. Liu T.C., and Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 67 (2007) 429-432
30. Park B.H., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a Phase I trial. Lancet Oncol. 9 (2008) 533-542
31. Vidal L., et al. A Phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin. Cancer Res. 14 (2008) 7127-7137
32. Tanaka H., et al. A replication-selective adenoviral vector for head and neck cancers. Arch. Otolaryngol. Head Neck Surg. 131 (2005) 630-634
33. Kim S.H., et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur. J. Cancer 41 (2005) 313-322
34. Reddy P.S., et al. Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin. Cancer Res. 12 (2006) 2869-2878
35. Hart L.S., et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J. Biol. Chem. 280 (2005) 1474-1481
36. Hart L.S., et al. The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage. J. Biol. Chem. 282 (2007) 6061-6067
37. Jarnagin W.R., et al. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther. 13 (2006) 326-334
38. Aghi M., et al. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl. Cancer Inst. 98 (2006) 38-50
39. Advani S.J., et al. Enhancing radiotherapy with genetically engineered viruses. J. Clin. Oncol. 25 (2007) 4090-4095
40. Bischoff J.R., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
41. Ries S.J., et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6 (2000) 1128-1133
42. McCormick F. ONYX-015 selectivity and the p14ARF pathway. Oncogene 19 (2000) 6670-6672
43. O'Shea C.C., et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6 (2004) 611-623
44. Ganly I., et al. A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6 (2000) 798-806
45. Nemunaitis J., et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55 kDa gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 60 (2000) 6359-6366
46. Nemunaitis J., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19 (2001) 289-298
47. Morley S., et al. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin. Cancer Res. 10 (2004) 4357-4362
48. Khuri F.R., et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 (2000) 879-885
49. Heise C., et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3 (1997) 639-645
50. Reid T., et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. 8 (2001) 1618-1626
51. Reid T., et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 62 (2002) 6070-6079
52. Nemunaitis J., et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8 (2001) 746-759
53. Nemunaitis J., et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10 (2003) 341-352
54. Yuan Z.Y., et al. Safety of an E1B deleted adenovirus administered intratumorally to patients with cancer. Ai Zheng 22 (2003) 310-313
55. Xu R.H., et al. Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer. Ai Zheng 22 (2003) 1307-1310
56. Lu W., et al. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot Phase II clinical trial. W. J. Gastroenterol. 10 (2004) 3634-3638
57. Xia Z.J., et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23 (2004) 1666-1670
58. Shen F.B., et al. Tumor-selective replication, cytotoxicity and GM-CSF production of oncolytic recombinant adenovirus in KH901 injection. Sichuan Da Xue Xue Bao Yi Xue Ban 38 (2007) 31-34
59. Chang J., et al. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol. Ther. 8 (2009) [epub ahead of print]
60. Fujimoto Y., et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 126 (2006) 1115-1117
61. Mace A.T., et al. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 127 (2007) 880-887
62. Takakuwa H., et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch. Virol. 148 (2003) 813-825
63. MacLean A.R., et al. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J. Gen. Virol. 72 Pt 3 (1991) 631-639
64. Markert J.M., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7 (2000) 867-874
65. Markert J.M., et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17 (2009) 199-207
66. Rothmann T., et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72 (1998) 9470-9478
67. Vollmer C., et al. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 59 (1999) 4369-4374
68. Geoerger B., et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62 (2002) 764-772
69. Ries S., and Korn W.M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer 86 (2002) 5-11
70. O'Shea C.C., et al. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8 (2005) 61-74
71. Querido E., et al. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J. Virol. 75 (2001) 699-709
72. Querido E., et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15 (2001) 3104-3117
73. Rainov N.G., and Ren H. Oncolytic viruses for treatment of malignant brain tumours. Acta Neurochir. Suppl. 88 (2003) 113-123
74. Zeimet A.G., and Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol. 4 (2003) 415-422
75. Stone D., et al. Comparison of adenoviruses from species B, C, E, and F after intravenous delivery. Mol. Ther. 15 (2007) 2146-2153
76. Stone D., et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 81 (2007) 4866-4871
77. Carlisle R.C., et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113 (2009) 1909-1918
78. Fisher K.D., et al. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J. Drug Target. 15 (2007) 546-551
79. Li C., et al. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 12 (2005) 913-925
80. Benedict C.A., et al. To kill or be killed: viral evasion of apoptosis. Nat. Immunol. 3 (2002) 1013-1018
81. Wang Y., et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotechnol. 21 (2003) 1328-1335
82. Todo T., et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6396-6401
83. Wohlfahrt M.E., et al. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res. 67 (2007) 8783-8790
84. Liu B.L., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10 (2003) 292-303
85. Doronin K., et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74 (2000) 6147-6155
86. Liu T.C., et al. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther. 12 (2005) 1333-1346
87. McCart J.A., et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 61 (2001) 8751-8757
88. McKee T.D., et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66 (2006) 2509-2513
89. Kim J.H., et al. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst. 98 (2006) 1482-1493
90. Tait D.L., et al. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5 (1999) 1708-1714
91. Raty J.K., et al. Non-invasive imaging in gene therapy. Mol. Ther. 15 (2007) 1579-1586
92. Merron A., et al. SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. Gene Ther. 14 (2007) 1731-1738
93. Winkeler A., et al. Switching on the lights for gene therapy. PLoS ONE 2 (2007) e528
94. Iyer M., et al. Applications of molecular imaging in cancer gene therapy. Curr. Gene Ther. 5 (2005) 607-618
95. McCart J.A., et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol. Ther. 10 (2004) 553-561
96. Serganova I., et al. Human reporter genes: potential use in clinical studies. Nucl. Med. Biol. 34 (2007) 791-807
97. Phuong L., et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 63 (2003) 2462-2469
98. Rudin C.M., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J. Clin. Oncol. 21 (2003) 4546-4552
99. Lowe S.W., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
100. Hamada M., et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol. 122 (1996) 360-365
101. Liao Y., and Hung M.C. A new role of protein phosphatase 2a in adenoviral E1A protein-mediated sensitization to anticancer drug-induced apoptosis in human breast cancer cells. Cancer Res. 64 (2004) 5938-5942
102. Lee W.P., et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res. 63 (2003) 6229-6236
103. Cheong S.C., et al. E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther. 15 (2008) 40-50
104. Bennett J.J., et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J. 18 (2004) 1001-1003
105. Stanziale S.F., et al. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery 132 (2002) 353-359